Maynard Um
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Cytokinetics (CYTK)
-
-
-
-
-
-
-
Cytokinetics (CYTK) Tops Q2 EPS by 13c
-
-
-
-
-
-
-
Cytokinetics presents new MYQORZO data at ESC Heart Failure 2026
-
-
-
-
-
-
-
Cytokinetics announces nine presentations at heart failure conference
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on Cytokinetics (CYTK) following conference
-
-
-
-
-
-
-
Cytokinetics gets European approval for heart drug MYQORZO
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $84 at Needham
-
470,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


